Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
Trillium Therapeutics shares soar on Pfizer’s $2.26B deal Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.